Market Size and Growth Highlights

The assisted reproductive technology market is on a steady path. Grand View Research estimates it at USD 27.6 billion in 2023 and USD 33.4 billion in 2026, then USD 41.4 billion by 2030. Put simply, the industry is expected to add roughly USD 13.8 billion in annual revenue between 2023 and 2030. That works out to about 21% growth across the first three years and a further 24% across the last four, so growth is not slowing as the base gets larger.

The pandemic is a useful reference point for resilience. Fertility treatments such as ovulation induction, artificial insemination, IVF and embryo transfers were halted or postponed in 2020. Procedure volumes dropped sharply in March and April 2020, yet the industry recovered quickly as the American Society for Reproductive Medicine, ESHRE and the International Federation of Fertility Societies resumed treatment guidance. The report headlines a 54% rebound from 2020 to 2021. Demand for fertility care was deferred rather than lost.

Telehealth is the next open lever. Its adoption in ART is still at an early stage, but remote monitoring and continuous patient management give it real potential for the 2026-2030 window.

The figures in this article draw on Grand View Research’s market analysis. Continue your research with their Prism AI tool for more data and insights.

Key Market Breakdown

By Type: IVF Leads, Insemination Grows Faster

IVF accounted for 91.90% of global revenue in 2022. Within IVF, frozen non-donor cycles are the standout. The 2019 national ART summary recorded about 126,187 frozen non-donor cycles, against 28,425 in 2010, a gain of more than four times in nine years. This reflects the shift toward freezing eggs or embryos for later transfer, which suits couples dealing with male-factor infertility or fallopian tube malformation.

Artificial insemination is the smaller segment, but it is forecast to grow fastest at an 8.58% CAGR. That is well above the 6.0% market average. It is used for minor fertility conditions, and often by same-sex couples and single women. According to the HFEA, per-cycle success rates run around 15.8% for women under 35, 11% for ages 35 to 39 and 4.7% for ages 40 to 42. More than half of women using intrauterine insemination conceive within six cycles. For patients, it is a lower-intensity route worth trying first.

By End-use: Specialized Clinics Hold the Lead

Fertility clinics and other facilities held over 79.93% of revenue in 2022 and are expected to keep the fastest growth. Specialization, expertise, customized treatment and cost-effectiveness explain the preference. Investment backs this up. In May 2021, Gulf Capital’s ART Fertility Clinics planned to invest USD 31.3 million in 18 clinics across major Indian cities by 2023.

Hospitals and other settings still matter in low- and middle-income countries. Where infrastructure for dedicated clinics is thin, multispecialty hospitals are often the most accessible place to get infertility treatment.

Download a free sample report or claim your copy of this full market intelligence report

By Region: Europe Leads, North America and Asia Pacific Follow

Europe held a 36.9% revenue share in 2023. ESHRE data suggests about 25 million people in the European Union live with infertility, the highest burden globally. North America is expected to see significant growth because of positive patient outcomes. In the U.S., the CDC reports that 2.1% of infants are born with ART assistance, with Massachusetts highest at 5.5%, followed by the District of Columbia at 5.0% and New Jersey at 4.4%. Asia Pacific is supported by research investment. Japan alone recorded about 458,101 ART cycles and 60,598 births in 2019 across 624 registered facilities.

Competitive Landscape

Competition centers on acquisitions and portfolio expansion. CooperCompanies acquired Generate Life Sciences, a donor egg and sperm supplier, for USD 1.6 billion in December 2021. CooperSurgical bought cryo-storage software provider Embryo Options in January 2021. Hamilton Thorne acquired IVFtech ApS for USD 8 million in July 2021. Other prominent names include Vitrolife, FUJIFILM Irvine Scientific, Merck KGaA, Ferring, Cryolab, European Sperm Bank and Bloom IVF Centre. The pattern is that consolidation is moving toward the whole treatment workflow: donor supply, storage software, lab equipment and culture media.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs

Key Drivers

Rising infertility. The WHO estimated in 2020 that about 186 million people worldwide face infertility. Contributing factors include sexually transmitted infections, smoking, obesity, endometriosis and PCOS. Chemotherapy and other fertility-threatening treatments add to the pool of patients.

Better technology and success rates. Pre-implantation genetic testing, endometrial receptivity analysis, magnetic activated cell sorting and time-lapse embryo imaging have made procedures more precise. Culture media research is also advancing. CooperSurgical found that media containing GM-CSF supplies nutrients for embryo development and supports communication between the embryo and the endometrium. Scale is growing too. The CDC’s 2019 report counted about 330,773 ART procedures at 448 U.S. clinics, resulting in 77,998 live births, or roughly 24 for every 100 procedures.

Awareness and income growth. Organizations such as ASRM and SART are widening understanding of treatment options. Rising disposable income in developing countries is turning that awareness into paid treatment, which also explains the hospital and clinic expansion in India and similar markets.

Supportive regulation. A favorable regulatory framework is listed among the core growth factors, alongside the health and lifestyle pressures above.

What This Means for the Assisted Reproductive Technology Market

The assisted reproductive technology market combines a large, established IVF base with a faster-growing insemination segment. Growth is supported by demand that proved durable even through COVID-19. Stakeholders should watch frozen-cycle technologies, clinic expansion in emerging economies and telehealth integration, as these are the areas where the data points to the strongest momentum.

Explore the full list of profiled companies operating in this market with recent strategic initiatives